<DOC>
	<DOCNO>NCT00824512</DOCNO>
	<brief_summary>The purpose protocol determine efficacy EGb 761 120 mg bid versus placebo patient suffer Friedreich Ataxia</brief_summary>
	<brief_title>Efficacy EGb761 Patients Suffering From Friedreich Ataxia</brief_title>
	<detailed_description />
	<mesh_term>Ataxia</mesh_term>
	<mesh_term>Cerebellar Ataxia</mesh_term>
	<mesh_term>Friedreich Ataxia</mesh_term>
	<criteria>Friedreich ataxia diagnosis confirm evidenced mutation expansion Frataxin gene Ambulatory patient , depress tendon reflex pyramidal syndrome associate loss position vibration sense dysarthria Patient able perform test study Severe cardiac disease assess echocardiography perform least within 6 month screen wash period ( 4 week ) Absolute contraindication Nuclear Magnetic Resonance spectroscopy ( NMR ) examination : iron magnetic object implant whole body , e.g . neurostimulators , cardiac pacemaker , vascular clip implant orthopaedic prosthesis Patient deplete baseline phosphocreatine ( PCr ) pool 30 % exercise bout Any continuous use follow forbidden medication : antioxidant idebenone , coenzyme Q , vitamin E/C take less 4 week prior study treatment start ( ie antioxidant drug mandatory washout period 4 week prior study drug start observe ) , vasodilator tranquilizer benzodiazepine , meprobamate buspirone , and/or antidepressant ( one ) , non stable dose</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>